JP2019500876A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500876A5
JP2019500876A5 JP2018535126A JP2018535126A JP2019500876A5 JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5 JP 2018535126 A JP2018535126 A JP 2018535126A JP 2018535126 A JP2018535126 A JP 2018535126A JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5
Authority
JP
Japan
Prior art keywords
culture
glycan
monoclonal antibody
man
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500876A (ja
JP6674028B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012349 external-priority patent/WO2017120347A1/en
Publication of JP2019500876A publication Critical patent/JP2019500876A/ja
Publication of JP2019500876A5 publication Critical patent/JP2019500876A5/ja
Application granted granted Critical
Publication of JP6674028B2 publication Critical patent/JP6674028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535126A 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節 Active JP6674028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (3)

Publication Number Publication Date
JP2019500876A JP2019500876A (ja) 2019-01-17
JP2019500876A5 true JP2019500876A5 (enExample) 2020-02-13
JP6674028B2 JP6674028B2 (ja) 2020-04-01

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535126A Active JP6674028B2 (ja) 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節

Country Status (8)

Country Link
US (1) US20190161543A1 (enExample)
EP (1) EP3400241B1 (enExample)
JP (1) JP6674028B2 (enExample)
CN (1) CN109153716A (enExample)
AU (1) AU2017206006B2 (enExample)
CA (1) CA3010598A1 (enExample)
MX (1) MX2018008447A (enExample)
WO (1) WO2017120347A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US12325737B2 (en) * 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
CA3123591A1 (en) * 2018-12-19 2020-06-25 Seagen Inc. Controlled fucosylation of antibodies
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies
US20240141020A1 (en) * 2021-02-12 2024-05-02 Lonza Bend Inc. Method for modulating afucoslyation of an antibody product

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
ATE515566T1 (de) 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
DK2808393T3 (en) 2009-06-02 2018-03-12 Regeneron Pharma Cells insufficient for fucosylation
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (enExample) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
CN108431026B (zh) * 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法

Similar Documents

Publication Publication Date Title
Li et al. Serum-free medium for recombinant protein expression in Chinese hamster ovary cells
Carrillo-Cocom et al. Amino acid consumption in naïve and recombinant CHO cell cultures: producers of a monoclonal antibody
JP6982578B2 (ja) 細胞培養培地
RU2642285C1 (ru) Способ получения целевого антитела с модулированным галактозилированием (варианты) и способ модулирования галактозилирования целевого антитела (варианты) путем оптимизации культуральной среды
Masterton et al. The impact of process temperature on mammalian cell lines and the implications for the production of recombinant proteins in CHO cells
RU2008152449A (ru) Получение гликопротеинов
IL201395A (en) Multi-clonal cell lines and methods for generating multi-clonal cell lines
RU2013152982A (ru) Способ снижения гетерогенности антител и способ получения соответствующих антител
UA120048C2 (uk) Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)
JP2022515820A5 (enExample)
JP2016513478A5 (enExample)
MX2018008447A (es) Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
IL313983A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
CN104560882A (zh) 一种降低酸性变体含量的cho细胞培养工艺
JP2016523910A5 (enExample)
MX2018008448A (es) Reducción de especies de alto peso molecular, especies con carga ácida, y fragmentos en una composición de anticuerpo monoclonal.
JP2022540920A (ja) 高密度連続接種の細胞培養方法及びその応用
Amribt et al. Optimization and robustness analysis of hybridoma cell fed-batch cultures using the overflow metabolism model
IL307155B1 (en) Antibodies with modulated glycan profiles
Yoon et al. Biphasic culture strategy for enhancing volumetric erythropoietin productivity of Chinese hamster ovary cells
Lee et al. Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture
Shi et al. Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation
Mahboudi et al. The role of different supplements in expression level of monoclonal antibody against human CD20
Fan et al. Effect of culture temperature on TNFR-Fc productivity in recombinant glutamine synthetase-chinese hamster ovary cells
CN103397034A (zh) miRNA-19a作为哺乳动物宿主细胞增殖调控靶标的应用